当前位置：
X-MOL 学术
›
Intensive Care Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?
Intensive Care Medicine ( IF 38.9 ) Pub Date : 2021-10-07 , DOI: 10.1007/s00134-021-06540-w Kate C Tatham 1, 2 , Manu Shankar-Hari 3, 4 , Yaseen M Arabi 5
中文翻译：
REMDACTA 试验：白介素受体拮抗剂对 COVID-19 有额外的益处吗？
更新日期：2021-10-07
Intensive Care Medicine ( IF 38.9 ) Pub Date : 2021-10-07 , DOI: 10.1007/s00134-021-06540-w Kate C Tatham 1, 2 , Manu Shankar-Hari 3, 4 , Yaseen M Arabi 5
Affiliation
中文翻译：
REMDACTA 试验：白介素受体拮抗剂对 COVID-19 有额外的益处吗？
京公网安备 11010802027423号